Beta-2-glycoprotein-1 and alpha-1-antitrypsin as urinary markers of renal cancer in von Hippel–Lindau patients

Abstract

Context: Von Hippel–Lindau disease (VHLD) is a rare inherited neoplastic syndrome. Among all the VHLD-associated tumors, clear cell renal cell carcinoma (ccRCC) is the major cause of death.

Objective: The aim of this paper is the discovery of new non-invasive biomarker for the monitoring of VHLD patients.

Materials and methods: We compared the urinary proteome of VHLD patients, ccRCC patients and healthy volunteers.

Results: Among all differentially expressed proteins, alpha-1-antitrypsin (A1AT) and APOH (beta-2-glycoprotein-1) are strongly over-abundant only in the urine of VHLD patients with a history of ccRCC.

Discussion and conclusion: A1AT and APOH could be promising non-invasive biomarkers.

Keywords:

• Von Hippel–Lindau disease
• renal cancer
• beta-2-glycoprotein-1 and alpha-1-antitrypsin
• urine
• proteomics

Acknowledgements

Authors thank Prof. Barbara Pasini and Prof. Mauro Maccario for the precious help in clinical aspects.

This work was supported by grants from University of Turin (ex 60%), the Associazione Italiana Ricerca sul Cancro (5 x mille no. 12182 and IG no. 15257) and Fondazione Ricerca Molinette.

Disclosure statement

The authors declare that they have no conflict of interest

Additional information

Funding

This work was supported by grants from University of Turin (ex 60%), the Associazione Italiana Ricerca sul Cancro (5 x mille no. 12182 and IG no. 15257) and Fondazione Ricerca Molinette.